NRBO - What's Going On With Clinical-Stage Biotech Firm NeuroBo Shares Today? | Benzinga
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) shares are trading lower in Friday's premarket session after ending Thursday's session with a whopping 21.2% gain.
The company has submitted an IND application to the FDA for a Phase 1 trial of DA-1726 for treating obesity.
The DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) for obesity.
Preclinical evidence shows that DA-1726 reduced food intake while increasing energy expenditure, ...